SG Spirit Gold Inc. (TSX VENTURE: SG) (“SG Spirit Gold” or the “Company“) is pleased to announce that it has appointed a syndicate of agents led by Mackie Research Capital Corporation (the “Lead Agent“) and including Canaccord Genuity Corp. and Eight Capital (together with the Lead Agent, the “Agents“) to sell by way of private placement up to 13,333,333 subscription receipts of the Company (the “Subscription Receipts“) at a price of $0.75 per Subscription Receipt for aggregate gross proceeds of up to $10,000,000 (the “Offering“).

Concurrent with the closing of the Transaction (as defined below), each Subscription Receipt shall be exchanged automatically, for no additional consideration, into units of the Company (the “Units“). Each Unit shall consist of one (1) common share of the Company (an “SG Share“) and one-half of one common share purchase warrant (each whole warrant, a “Warrant“). Each Warrant shall entitle the holder to acquire one (1) additional Common Shares at an exercise price of $1.25 for a period of 24 months from the date of issuance. Subscribers identified by the Company will be entitled to participate for up to $5 million of the Offering (the “President’s List“).

In accordance with the terms and conditions of an amalgamation agreement between the Company, NLMCO Acquisition Corp. (“Acquireco“) and Northern Lights Marijuana Company Limited (“DOJA“) dated February 10, 2017 (the “Amalgamation Agreement“), the Company has agreed, subject to the receipt of all necessary approvals, to complete a business combination with DOJA. Pursuant to the terms of the Amalgamation Agreement, each holder of DOJA shares (the “DOJA Shares“) will transfer their DOJA Shares to the Company in exchange for SG Shares on the basis 1.8 SG Shares for each DOJA Share transferred. Concurrently, DOJA and Acquireco, a wholly-owned subsidiary of SG Spirit, will amalgamate to form a new entity wholly-owned by the Company (the “Transaction“). In connection with the Transaction, it is anticipated that the Company will apply to listing the SG Shares on the Canadian Securities Exchange, and voluntarily delist the SG Shares from the TSX Venture Exchange. It is also anticipated that the Company will change its name to “DOJA Cannabis Company Limited”.

It is anticipated that the net proceeds of the Offering will be used to (i) fund a $8,000,000 Phase II expansion at DOJA’s West Kelowna facility, (ii) fund a land acquisition to secure Phase III expansion plans in the Okanagan, and (iii) for working capital and general corporate purposes.

The Subscription Receipts will be offered in all provinces of Canada and such other jurisdictions as the Company and the Agents may agree and where the Offering can be sold without the requirement to file a prospectus or similar document.

In consideration for the Agents’ services in connection with the Offering, the Company has agreed to pay the Agents a cash commission equal to 7.0% (3.0% in the case of President’s List) of the aggregate gross proceeds arising from the Offering. In addition, the Company has agreed to issue the Agents options equal in number to up to 7.0% (3.0% in the case of President’s List) of the number Subscription Receipts sold under the Offering. Closing of the Offering is expected to occur on or about April 24, 2017.

About DOJA
DOJA is a privately-owned company based in Canada’s picturesque Okanagan Valley that is committed to becoming a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations (“ACMPR“) and building a fast growing lifestyle brand that offers the highest quality handcrafted cannabis strains in Canada.

DOJA was founded in 2013 by the same team that founded and built SAXX Underwear into an internationally recognizable brand. The DOJA team plans to build upon their past success in the consumer packaged goods industry and their mutual interest in, and appreciation for, cannabis culture and grow DOJA into a market leading brand in the cannabis industry.

DOJA has completed the build-out of its state-of-the-art-facility, capable of producing more than 650 kilograms of marijuana annually, and has notified Health Canada’s Office of Medical Cannabis that DOJA’s proposed site is ready for Health Canada to conduct a Pre-License Inspection. The issuance of a license under the ACMPR is, in part, dependent upon the completion of a satisfactory Pre-License Inspection by Health Canada.

For further information please contact Richard Grayston, Chief Executive Officer of the Company at or Jeff Barber, Chief Financial Officer of DOJA at or visit DOJA’s website at for further information.

On behalf of the Board,

SG Spirit Gold Inc.

Richard Grayston, Chief Executive Officer

Forward-Looking Information
This news release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations. When used in this news release, the words estimate”, project”, belief”, anticipate”, intend”, expect”, plan”, predict”, may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this news release include information relating to the business plans of the Company and DOJA, the Offering and the Transaction. Such statements and information reflect the current views of the Company.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks:

  • there is no assurance that the Company and DOJA will obtain all requisite approvals for the
  • following completion of the Transaction, the Company may require additional financing from
    time to time in order to continue its operations; financing may not be available when needed or on
    terms and conditions acceptable to the Company;
  • new laws or regulations could adversely affect the Company’s business and results of operations;
  • the stock markets have experienced volatility that often has been unrelated to the performance of
    companies. These fluctuations may adversely affect the price of the Company’s securities,
    regardless of its operating performance.

The Company cautions that the foregoing list of material factors is not exhaustive. When relying on the Company’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.


Readers are cautioned that closing of the Transaction remains subject to a number of conditions, including receipt of any required shareholder, regulatory and third-party consents, the Canadian Securities Exchange having conditionally accepted the listing of the Company’s common shares, the TSX Venture Exchange having consented to the voluntarily delisting of the Company’s common shares, and the satisfaction of other customary closing conditions. The Transaction cannot close until the required approvals are obtained, and the Company’s common shares have been delisted from the TSX Venture Exchange. There can be no assurance that the Transaction will be completed as proposed or at all, or that the Company’s common shares will be listed and posted for trading on any stock exchange.

Neither the TSX Venture Exchange, nor the Canadian Securities Exchange, has in any way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.


The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less